[CDXS] Codexis, Inc.

Overview

Type of security: Stock

Sector: Basic Industries

Industry: Major Chemicals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.85 Change: 0.15 (3.19%)
Ext. hours: Change: 0 (0%)

chart CDXS

Refresh chart

Strongest Trends Summary For CDXS

CDXS is in the medium-term down -42% below S&P in 1 year. In the long-term up 619% in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

Fundamental Ratios
Shares Outstanding EPS-0.23 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.47% Sales Growth - Q/Q-52.1% P/E-20.87
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-44.08% ROE-84.46% ROI
Current Ratio2.33 Quick Ratio2.24 Long Term Debt/Equity Debt Ratio0.55
Gross Margin75.28% Operating Margin-52.08% Net Profit Margin-52.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-430 K Cash From Investing Activities-60 K Cash From Operating Activities-3.84 M Gross Profit5.34 M
Net Profit-5.56 M Operating Profit-5.53 M Total Assets41.42 M Total Current Assets27.63 M
Total Current Liabilities11.87 M Total Debt Total Liabilities19.8 M Total Revenue6.8 M
Technical Data
High 52 week22.57 Low 52 week13.35 Last close14.17 Last change0.07%
RSI15.42 Average true range0.74 Beta1.16 Volume24.04 K
Simple moving average 20 days-19.88% Simple moving average 50 days-21.48% Simple moving average 200 days-24.42%
Performance Data
Performance Week-19.31% Performance Month-24.39% Performance Quart-28.29% Performance Half-34.15%
Performance Year6.14% Performance Year-to-date-15.15% Volatility daily3.98% Volatility weekly8.89%
Volatility monthly18.22% Volatility yearly63.12% Relative Volume202.67% Average Volume386.81 K
New High New Low

News

2020-05-22 19:31:54 | Should Codexis Investors Prepare for Slower Growth?

2020-05-11 07:00:10 | Codexis to Present at the UBS Virtual Healthcare Conference

2020-05-11 06:51:41 | H.C. Wainwright Sticks to Their Buy Rating for Codexis

2020-05-09 01:30:56 | CodexisCDXS Q1 2020 Earnings Call Transcript

2020-05-08 14:13:52 | Edited Transcript of CDXS earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-07 16:05:10 | Codexis Reports First Quarter 2020 Financial Results

2020-05-06 16:05:10 | Codexis Achieves Technology Transfer Milestone with Global Pharmaceutical Leader

2020-05-05 07:00:10 | Codexis Expands and Strengthens its Leadership Team with Two Executive Hires

2020-04-30 07:00:10 | Codexis to Hold First Quarter 2020 Conference Call on May 7

2020-04-27 12:31:04 | Earnings Preview: Codexis CDXS Q1 Earnings Expected to Decline

2020-04-07 08:37:23 | Is Codexis, Inc.'s NASDAQ:CDXS CEO Pay Justified?

2020-03-23 07:00:10 | Codexis Signs Strategic Collaboration and License Agreement with Takeda to Advance Novel Gene Therapies for Rare Genetic Disorders

2020-03-13 13:57:07 | Edited Transcript of CDXS earnings conference call or presentation 27-Feb-20 9:30pm GMT

2020-03-02 10:15:03 | Company News for Mar 2, 2020

2020-03-01 07:19:54 | Analysts Have Been Trimming Their Codexis, Inc. Price Target After Its Latest Report

2020-02-27 18:55:11 | Codexis CDXS Q4 Earnings and Revenues Lag Estimates

2020-02-27 16:05:10 | Codexis Reports 2019 Fourth Quarter and Full Year Financial Results

2020-02-25 07:00:10 | Codexis to Present at Two Investment Conferences in March

2020-02-20 07:00:10 | Codexis to Hold 2019 Fourth Quarter and Full Year Conference Call on February 27

2020-01-31 07:52:55 | Have Insiders Been Buying Codexis, Inc. NASDAQ:CDXS Shares This Year?

2020-01-13 16:05:10 | Codexis Attends Opening Ceremony for Porton’s Fermentation Pilot Lab in Chongqing

2020-01-10 07:00:10 | Codexis and Nestlé Health Science Sign Development Agreement to Advance Therapeutic Candidate towards Clinical Studies and Extend Strategic Collaboration Agreement

2020-01-01 09:06:21 | We're Not Very Worried About Codexis's NASDAQ:CDXS Cash Burn Rate

2019-12-24 07:24:51 | The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict

2019-12-23 07:00:10 | Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing

2019-12-16 06:10:17 | Hedge Funds Are Dumping Codexis, Inc. CDXS

2019-12-05 16:05:10 | Codexis Announces the Publication with Merck of an Efficient Enzymatic Cascade Process for Synthesis of Investigational Anti-HIV Agent, Islatravir

2019-12-02 12:32:50 | Codexis NASDAQ:CDXS Shareholders Have Enjoyed A Whopping 567% Share Price Gain

2019-11-06 09:00:02 | Codexis CDXS Upgraded to Buy: What Does It Mean for the Stock?

2019-11-06 06:08:24 | Edited Transcript of CDXS earnings conference call or presentation 5-Nov-19 9:30pm GMT

2019-11-05 19:55:12 | Codexis CDXS Q3 Earnings and Revenues Beat Estimates

2019-11-05 16:05:00 | Codexis Reports Third Quarter 2019 Financial Results

2019-11-05 07:00:05 | Codexis to Participate in Four Investment Conferences in November

2019-10-29 07:00:05 | Codexis to Hold Third Quarter 2019 Conference Call on November 5

2019-10-27 20:13:14 | Is Codexis, Inc. CDXS A Good Stock To Buy ?

2019-10-26 09:13:00 | A Look At The Fair Value Of Codexis, Inc. NASDAQ:CDXS

2019-10-15 16:05:00 | Codexis’ Protein Engineering Forum Highlights Progress and Future Direction of the Field

2019-09-26 08:00:00 | Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit

2019-09-26 07:00:00 | Codexis to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

2019-09-20 06:57:54 | Is Codexis, Inc.'s NASDAQ:CDXS CEO Pay Justified?

2019-08-29 07:11:00 | 3 Top Stocks Under $20

2019-08-22 23:15:03 | Codexis Inc CDXS President and CEO John J Nicols Bought $133,000 of Shares

2019-08-09 13:32:50 | Edited Transcript of CDXS earnings conference call or presentation 6-Aug-19 8:30pm GMT

2019-08-07 15:49:08 | Codexis Rolls Into Second Half Armed with Cash

2019-08-07 08:25:49 | CodexisCDXS Q2 2019 Earnings Call Transcript

2019-08-06 19:35:11 | Codexis CDXS Reports Q2 Loss, Lags Revenue Estimates

2019-08-06 16:06:00 | Codexis Reports Second Quarter 2019 Financial Results

2019-07-30 07:00:00 | Codexis to Hold Second Quarter 2019 Conference Call on August 6

2019-06-27 15:01:00 | 3 Top Stocks Under $20

2019-06-20 07:00:00 | Casdin Capital Invests $50 Million in Codexis to Accelerate Strategic Growth Initiatives